JP2007505826A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505826A5 JP2007505826A5 JP2006525792A JP2006525792A JP2007505826A5 JP 2007505826 A5 JP2007505826 A5 JP 2007505826A5 JP 2006525792 A JP2006525792 A JP 2006525792A JP 2006525792 A JP2006525792 A JP 2006525792A JP 2007505826 A5 JP2007505826 A5 JP 2007505826A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sequence
- polypeptide
- acid molecule
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 7
- 108020005544 Antisense RNA Proteins 0.000 claims description 4
- 239000003184 complementary RNA Substances 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 108010077544 Chromatin Proteins 0.000 claims 17
- 210000003483 chromatin Anatomy 0.000 claims 17
- 238000000926 separation method Methods 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000012512 characterization method Methods 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000000054 Coronary Restenosis Diseases 0.000 claims 2
- 206010056489 Coronary artery restenosis Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000000061 acid fraction Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 238000007423 screening assay Methods 0.000 claims 2
- 239000007790 solid phase Substances 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 208000012766 Growth delay Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000002825 functional assay Methods 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50265303P | 2003-09-15 | 2003-09-15 | |
| PCT/EP2004/010311 WO2005026388A2 (en) | 2003-09-15 | 2004-09-15 | The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505826A JP2007505826A (ja) | 2007-03-15 |
| JP2007505826A5 true JP2007505826A5 (enExample) | 2007-11-08 |
Family
ID=34312412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525792A Withdrawn JP2007505826A (ja) | 2003-09-15 | 2004-09-15 | 増殖性疾患の診断および治療において、クロマチン分離に影響を与える真核生物遺伝子の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070042981A1 (enExample) |
| EP (1) | EP1682574A2 (enExample) |
| JP (1) | JP2007505826A (enExample) |
| AU (1) | AU2004272738A1 (enExample) |
| CA (1) | CA2538495A1 (enExample) |
| WO (1) | WO2005026388A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2921064A1 (fr) * | 2007-09-14 | 2009-03-20 | Biomerieux Sa | Oligonucleotides, utilisation, methode de detection et kit permettant de diagnostiquer la presence du gene e1 du virus du chikungunya |
| US20220096391A1 (en) * | 2018-12-28 | 2022-03-31 | President And Fellows Of Harvard College | Unidirectional presentation of membrane proteins in nanoparticle-supported liposomes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0723595A1 (en) * | 1993-10-22 | 1996-07-31 | The Board Of Regents, The University Of Texas System | A novel nuclear mitotic phosphoprotein: mitosin |
| US6331424B1 (en) * | 1999-04-20 | 2001-12-18 | Cytokinetics, Inc. | Motor proteins and methods for their use |
| EP1254224A2 (en) * | 2000-02-09 | 2002-11-06 | Pharma Pacific Pty. Ltd. | Interferon-alpha induced genes |
| AU2002324700A1 (en) * | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
| US20040009156A1 (en) * | 2001-10-12 | 2004-01-15 | Christoph Reinhard | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer |
-
2004
- 2004-09-15 CA CA002538495A patent/CA2538495A1/en not_active Abandoned
- 2004-09-15 WO PCT/EP2004/010311 patent/WO2005026388A2/en not_active Ceased
- 2004-09-15 AU AU2004272738A patent/AU2004272738A1/en not_active Abandoned
- 2004-09-15 JP JP2006525792A patent/JP2007505826A/ja not_active Withdrawn
- 2004-09-15 US US10/572,123 patent/US20070042981A1/en not_active Abandoned
- 2004-09-15 EP EP04765225A patent/EP1682574A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke | |
| JP2009519002A5 (enExample) | ||
| JP2007506426A5 (enExample) | ||
| Yu et al. | Identification of the gene transcription and apoptosis mediated by TGF‐β‐Smad2/3‐Smad4 signaling | |
| AU5099999A (en) | Cis acting nucleic acid elements and methods of use | |
| EP3455379B1 (en) | Ribonucleic acid (rna) interactions | |
| Niemeyer | Changing calcium: CRAC channel (STIM and Orai) expression, splicing, and posttranslational modifiers | |
| Sun et al. | Transcriptome identified lncRNAs associated with renal fibrosis in UUO rat model | |
| JP2012501164A5 (enExample) | ||
| Iranfar et al. | Transcriptional regulation of post-aggregation genes in Dictyostelium by a feed-forward loop involving GBF and LagC | |
| JP2008502332A5 (enExample) | ||
| Natua et al. | Hypoxia-induced alternative splicing in human diseases: the pledge, the turn, and the prestige | |
| Kiryu-Seo et al. | The nuclear events guiding successful nerve regeneration | |
| CA2428438A1 (en) | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases | |
| JP2004526421A5 (enExample) | ||
| JP2005511023A5 (enExample) | ||
| EP2917363B1 (en) | Means and methods for identifying ribosome associated rna molecules | |
| Chen et al. | Homology with vesicle fusion mediator syntaxin-1a predicts determinants of epimorphin/syntaxin-2 function in mammary epithelial morphogenesis | |
| JP2007505826A5 (enExample) | ||
| Dayem et al. | Early gene expression in wounded human keratinocytes revealed by DNA microarray analysis | |
| JP2007505825A5 (enExample) | ||
| Chen et al. | A novel gene IC53 stimulates ECV304 cell proliferation and is upregulated in failing heart | |
| JP2007505824A5 (enExample) | ||
| JP2007508020A5 (enExample) | ||
| Hecht et al. | Gene identification and analysis of transcripts differentially regulated in fracture healing by EST sequencing in the domestic sheep |